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Abstract
Graft-versus-host disease is one of the most frequent complications occurring after haematopoietic
stem cell transplantation. Recently, renal involvement has been described as a manifestation of
chronic graft-versus-host disease. Immunosuppression seems to play a major role: clinical disease
is triggered by its tapering and resolution is achieved with the resumption of the
immunosuppressive therapy. Prognosis is apparently favourable, but long term follow up data are
lacking.
We report a case of a 53-year-old man who developed nephrotic syndrome 142 days after
allogeneic stem cell transplantation for acute myeloid leukaemia. Onset of nephrotic syndrome
occurred after reduction of immunosuppressants and was accompanied by manifestations of
chronic graft-versus-host disease. Histological examination of the kidney was consistent with
Minimal Change Disease. After treatment with prednisolone and mycophenolate mofetil he had
complete remission of proteinuria and improvement of graft-versus-host disease. Eighteen months
after transplantation the patient keeps haematological remission and normal renal function, without
proteinuria.
Since patients with chronic graft-versus-host disease might be considered at risk for development
of nephrotic syndrome, careful monitoring of renal parameters, namely proteinuria, is advisable.
Case presentation
A 53-year-old hypertensive man with adenomatous
colonic polyposis was found to have acute myeloid leu-
kaemia (AML) M2 after diagnostic workup of rectal bleed-
ing.
He had consanguine parents. His father died at 90 and his
mother at 76 years. They had no known colonic polyps or
history of colonic cancer. He had 3 brothers: two healthy,
with 60 and 61 years and a 56 year-old with AML M3 who
has been submitted to a total colectomy due to adenoma-
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tous colonic polyposis. Colonoscopic screening was,
unsuccessfully, attempted in the patient's offspring. At the
time of AML diagnosis, March 2005, no chromosomal
abnormalities were detected in the leukaemic blasts. First
complete remission was achieved in April 2005 with
Cytarabin/Idarubicin. A relapse was identified 4 months
later and the patient was treated with Carboplatin/Etopo-
side. After this second remission, he underwent peripheral
blood stem cell transplant (PBSCT) from an HLA-identi-
cal brother in December 2005. Reduced-intensity condi-
tioning was performed with Fludarabine/Busulfan and
graft-versus-host disease (GVHD) prophylaxis with
Cyclosporine (CsA)/Methotrexate. Platelet and neu-
trophil recovery to > 20 × 109/L and > 0.5 × 109/L respec-
tively, were achieved on days +10 and +18,
correspondingly. A 100% donor chimerism was con-
firmed. Regimen haematological toxicities were minimal,
but he developed acute GVHD (skin +3/global II, of the
1994 Consensus Conference on Acute GVHD Grading)
with maculopapular rash on day +20 after transplant.
Complete response to prednisolone was reached. A CMV
infection was identified on day +30 and treated with val-
ganciclovir.
On day +142 the patient was admitted with anasarca. He
claimed of dry, painful eyes and xerostomia that started a
few weeks ago. He was afebrile, with blood pressure of
140/92 mmHg, pulse of 80 bpm, with no respiratory dis-
tress. He had no organomegalies but facial and lower
limbs oedema was identified. Pigmented lesions (poikilo-
derma), lichen planus-like eruptions, sclerotic features
characterized by thickened skin and maculopapular rash
in the palmar and facial regions were present.
At this time point his medication was: CsA 50 mg q12h,
prednisolone 30 mg qod, enalapril 20 mg qd, bisoprolol
5 mg qd, sulfamethoxazole/trimethoprim 960 mg three
times a week, acyclovir, mianserine, folate and magne-
sium. CsA and prednisolone have been progressively
tapered, as planned.
He had de novo severe proteinuria (14 g/24 h), hypoalbu-
minemia (2 g/dL), hypercholesterolemia (243 mg/dL),
acute renal failure (creatinine 2 mg/dL; urea 102 mg/dL)
and an erythrocyte count of 8 cells/hpf, leucocyturia and
hyaline-granular casts in the urine test. A diagnosis of
nephrotic syndrome (NS) was rendered.
Hepatic enzymes were increased: AST 173 U/L, ALT 253
U/L, alkaline phosphatase 505 U/L, GGT 1637 U/L,
5'nucleotidase 244 U/L and total bilirubin 2.7 mg/dL.
Hematologic findings included anemia (7 g/dL), throm-
bocytopenia (43 000) and reticulocytosis (7%); the leuko-
cyte count was normal. A peripheral blood smear showed
no evidence of microangiopathy. Increased serum lactic
dehydrogenase, indirect bilirubin and low haptoglobin
were also found. Direct Coomb's test and anti-platelet
antibodies were positive. Prothrombin time, activated
partial thromboplastin time and fibrinogen were within
reference range. Antinuclear antibody, anti-ds DNA, cry-
oglobulin and hypocomplementemia were not present.
Serum immunoglobulins were within normal limit. Tests
for hepatitis B virus surface antigen, hepatitis C and HIV
antibody, CMV IgM, CMV pp65 antigen, EBV IgM and
serological tests for adenoviruses and parvovirus B19 were
negative. Culture for bacteria and fungi revealed no
microbiological growth. Serum/urinary immunoelectro-
phoresis disclosed no monoclonal proteins. CsA trough
level was 97 ng/mL. Abdominal ultrasonography and
chest X-rays were normal. A pelvic magnetic resonance
was normal and excluded renal venous thrombosis.
Relapse of AML was excluded.
CsA was withdrawn and a percutaneous renal biopsy was
performed. Pathological examination disclosed 15
glomeruli, with patent lumina and absence of increased
mesangial cellularity or matrix deposition (figure 1). Mor-
phologic features of acute tubular necrosis (figure 2) were
found without evident hyaline thrombi. No immune
deposits were detected by fluorescence microscopy.
Ultrastructural analysis disclosed only diffuse podocyte
fusion (figure 3). Thus, a diagnosis of Minimal Change
Disease and acute tubular necrosis was revealed.
Renal biopsy specimen (HE): An essentially normal  glomerulus, with open capillary lumens and only minimal  hypercellularity Figure 1
Renal biopsy specimen (HE): An essentially normal 
glomerulus, with open capillary lumens and only minimal 
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Treatment with high dose corticosteroids (i.v. methyl-
prednisolone 1 g × 3 days followed by oral prednisolone
1 mg/kg/day) and mycophenolate mofetil (MMF 1 g bid)
was started and complete remission of proteinuria was
achieved 4 weeks later (figure 4). NS was complicated by
thrombosis in the femoropopliteal veins of the right leg
(three weeks after hospital admission) and the patient was
placed on anticoagulant therapy. During hospitalization
he developed new onset of diplopia. A right petroclival
meningioma was diagnosed by magnetic resonance. The
management was conservative, with clinical surveillance.
At the present time he has no diplopia. A gastroenterology
consultation concluded that the patient had attenuated
familial adenomatous polyposis. Colonic polyps showed
regression after therapy with sulindac. Search for muta-
tions at the APC and MYH loci was negative.
Currently, 18 months after transplantation, the patient
maintains haematological remission, normal kidney and
hepatic function and urinary protein loss of less than 0.3
g/24 h. He is still on immunosuppressive therapy with
MMF 1 g bid and prednisolone 10 mg every other day due
to ocular GVHD.
Background
Haematopoietic stem cell transplantation (HSCT) is an
increasing therapeutic option for a variety of malignant
and non malignant haematological diseases. Renal com-
plications associated with this procedure have an omi-
nous prognosis [1]. Imai et al [1] classified HSCT-related
nephropathy into three groups according to the time of
onset. During the early post transplant period sepsis,
tumour lysis syndrome, hepatic venooclusive disease and
nephrotoxicity may cause acute renal failure. Middle-
onset includes haemolytic uremic syndrome/thrombotic
thrombocytopenic purpura. After 6 months multifactorial
chronic renal failure is a recognized sequela of HSCT.
Recently, nephrotic syndrome (NS) after HSCT has been
reported, usually associated with graft-versus-host disease
(GVHD) [2]. Imai group [1] described 8 NS cases in 2136
stem cell recipients. An extensive literature review identi-
fied 46 case reports [2]; recently, 4 further cases [3] were
described.
GVHD is the most common late complication of HSCT,
occurring in 60–80% of long term survivors and causing
significant morbidity and mortality [4]. In the past, any
manifestation of GVHD that was present at 100 or more
days after HSCT was arbitrarily defined as chronic GVHD.
This definition had been questioned and the current con-
sensus of the National Institutes of Health [5] is that clin-
ical manifestations, and not time, determine whether the
clinical syndrome is considered acute or chronic. GVHD
resembles autoimmune disorders such as Sjögren syn-
drome but the physiopathology is far from clear. The skin,
the liver, the gut and the eyes are frequently damaged;
conversely, kidney [2] and haematopoietic system [6] are
seldom involved. The main risk factor for chronic GVHD
Renal biopsy specimen (Electron micrograph × 10000):  Epithelial cells effaced along the glomerular basement mem- brane Figure 3
Renal biopsy specimen (Electron micrograph × 10000): 
Epithelial cells effaced along the glomerular basement mem-
brane.
Renal biopsy specimen (HE): focal loss of tubular epithe- lial cells and presence of cellular debris inside of the tubules,  consistent with acute tubular necrosis; no interstitial fibrosis  was present Figure 2
Renal biopsy specimen (HE): focal loss of tubular epithe-
lial cells and presence of cellular debris inside of the tubules, 
consistent with acute tubular necrosis; no interstitial fibrosis 
was present. Immunofluorescence (not shown) was negative.Journal of Medical Case Reports 2007, 1:121 http://www.jmedicalcasereports.com/content/1/1/121
Page 4 of 6
(page number not for citation purposes)
is HLA mismatch. Its incidence is also higher in older
recipients, gender mismatch (female donor to male recip-
ient), allogeneic versus autologous and PBSCT versus
bone marrow transplantation (BMT) [7].
Pathological diagnosis of GVHD-related NS is essentially
Membranous Nephropathy (MN) in two thirds and Min-
imal Change Disease (MCD) in nearly one quarter of
patients [2,8]. However, as recently confirmed, a wide
spectrum of renal diseases can be found: focal segmental
glomerulonephritis [2] including the "tip variant" [9], dif-
fuse proliferative glomerulonephritis [10], IgA nephropa-
thy [11], membranoproliferative glomerulonephrities [3]
and antineutrophil cytoplasmic antibody-associated
glomerulonephritis [12].
Typically, a temporal relation between NS, cessation/
tapering of immunosupressants and simultaneous GVHD
is seen. NS generally, responds well to immunosupressive
therapy, but this seemingly good prognosis has to be
weighed against our limited knowledge in this setting.
Discussion
Herein, we present a case of MCD at +142 day after
PBSCT. MCD is a rare complication of HSCT, with only 10
cases reported thus far. In these 10 patients, the underly-
ing predominant haematological disease was AML; when
overall HSCT related NS are considered the most frequent
diagnosis was Chronic Myeloid Leukaemia.
Almost all reviewed cases were myeloablative transplants.
However, a cohort study [13] identified nonmyeloabla-
tive HSCT as a risk factor for NS. In this six-year experi-
ence, seven of 163 patients (4.3%) after
nonmyeloablative transplant, as opposed to none of 118
patients after myeloablative transplant, developed this
complication.
Peripheral blood compared to bone marrow cells, is
increasingly used as a source of haematopoietic stem cells.
Some studies suggested an increased GVHD incidence
with the former, which may be explained by the transfer
of a greater T cell dose with the PBSCT. In a report from
Colombo et al [14] patients grafted with peripheral stem
cells have a 24% and those with bone marrow have a 3%
probability of developing NS. Consequently, in the near
future, we might expect an increased number of glomeru-
lar diseases after HSCT.
Seconi et al [15] recently proposed an association between
NS following GVHD and an increased production of
Tumor Necrosis Factor alpha (TNFα) by donor T cells.
They established that excessive TNFα and Interferon
gamma (IFNγ) were implicated in the development of
skin and gut GVHD and that high TNFα production had a
role in the development of idiopathic NS. Consequently,
TNFα might be seen as a target for future therapeutic
options.
MCD usually appeared early after HSCT (median 8 versus
14 months for MN) [2]. The most common clinical man-
ifestations were fatigue and oedema [14]. The median pre-
senting plasma creatinine and proteinuria values were 1.2
mg/dL and 13 g/day, respectively [14]. Auto antibodies
and serum complement levels were typically normal.
The most striking feature of HSCT related NS was the asso-
ciation with GVHD. Indeed, the majority of patients
reported had evidence of acute and/or chronic GVHD.
GVHD was simultaneous in 3 and preceded NS in 4 of the
10 MCD patients [2]. Nevertheless, there are at least 3
cases of NS after HSCT without evidence of GVHD.
Changes in immunosuppressant doses were reported in
the majority of patients. The time course between discon-
tinuation and/or tapering of immunosuppressants and
NS onset suggests the former as a risk factor.
Therapeutic options included mostly steroids and
cyclosporine, but other agents like cyclophosphamide,
tacrolimus, MMF and rituximab had been used [12].
Nonetheless, so far, ideal treatment, dose, duration or tar-
get levels of immunosuppressive medications is still
unknown.
Similar to idiopathic MCD, almost all patients achieved
complete remission and response was generally reached
after 8–10 weeks of treatment [1]. However, concerning
MN, prognosis does not seem so favourable: only 27%
showed complete and 62% partial remission, in Ratanath-
arathorn's study [4]. Furthermore, a poor response and a
high propensity for progressive renal failure were
described by others [10]. In addition, the majority of the
authors do not make substantial comments on long term
follow-up or on the potential deleterious effect of
increased immunosupression. Conversely, Kemper and
colleagues [3], described 3 MN cases with a sustained
remission of the NS.
Among the reported post-HSCT nephrotic cases, haemo-
lytic anaemia and immune thrombocytopenia are
uncommon. However, autoimmune cytopenias are part
of the chronic GVHD spectrum and are caused by anti-
bodies [5,6] of donor origin directed against the recipient
red cell/platelet antigens. Among patients who developed
chronic GVHD, Godder and co-authors [6] reported five
cases (28%) presenting with haemolytic anaemia (HA)
with or without thrombocytopenia. Along with a mean
haemoglobin level of 7.1 g/dL, patients had an increased
reticulocyte count, a mild raised lactic acid dehydroge-Journal of Medical Case Reports 2007, 1:121 http://www.jmedicalcasereports.com/content/1/1/121
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nase, an increased indirect bilirubin and a positive
Coombs' test. Our patient showed similar findings. The
evidence of an immune-mediated process (as suggested
by the positive Coombs' test and platelet antibody) and
the response to intensive immunosuppressive therapy
with simultaneous regression of chronic GVHD lesions
supported our diagnosis of involvement of the haemat-
opoietic system by GVHD.
Acute renal failure in our patient was due to acute tubular
necrosis. A reduction in glomerular filtration rate may be
seen in MCD. Aetiologies include ischemic injury, intersti-
tial oedema with tubular collapse, excessive diuretic use or
anti-inflammatory drugs. Renal vein thrombosis is
another possible cause, but was excluded in our case.
Biopsy specimens confirmed changes similar to that seen
in postischemic acute tubular necrosis.
Although a liver biopsy and a Schirmer test were not per-
formed we assumed hepatic and ocular involvement by
chronic GVHD due to the fact that concomitant and dis-
tinctive manifestations in the skin were present. Fading of
hepatic and ocular lesions concomitant with vanishing of
the GVHD with immunosuppression do support our
hypothesis.
Here, we reported a case of an allogeneic PBSCT recipient
who developed chronic GVHD according to Filipovich's
classification [5]. Cutaneous (poikiloderma and sclerotic
features), ocular (xerophthalmia), hepatic (cholestasis),
hematological (autoimmune cytopenias) and renal
(nephrotic syndrome) involvement by GVHD was identi-
fied. To the best of our knowledge this is the first reported
case of GVHD with involvement of both the kidney and
the haematopoietic system, two exceptional manifesta-
tions of GVHD.
Conclusion
NS is a well-characterized, although unusual complica-
tion of HSCT that occurs in association with GVHD flares
after taper of immunosuppression. The reviewed literature
suggests that glomerular lesions actually represent renal
GVHD, but pathophysiology is unclear and warrants fur-
ther investigation. Longer follow-up of larger cohorts is
mandatory to identify definitive HSCT related NS risk fac-
tors.
Data on glomerulopathies, in addition to renal function,
should be routinely collected and recorded as part of BMT
complications.
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